Shift work disrupts the circadian clock in ways that are not easily repaired by sleep hygiene alone. A worker rotating from night to day shifts often experiences early-morning awakenings, fragmented sleep, and a persistent sense of anxiety that further prevents rest. In Russian peptide research, Selank (a synthetic heptapeptide analogue of tuftsin) has been studied for its anxiolytic and sleep-stabilizing properties. The question here is whether Selank can address sleep maintenance problems in shift workers who are also using Retatrutide (a triple agonist of GLP-1, GIP, and glucagon receptors). Retatrutide is primarily investigated for metabolic effects, but its influence on sleep architecture and circadian timing is not yet well characterized. This article examines the available literature, mostly from Russian sources, on Selank's potential to prevent early-morning awakenings and support circadian re-entrainment in this specific population.
The Russian Research School on Peptide Bioregulators
Russian peptide research has a long tradition, with figures like Vladimir Khavinson and Vladimir Anisimov leading studies on short peptides for neuroendocrine and circadian regulation. Khavinson's work on Epitalon (a tetrapeptide) demonstrated effects on pineal melatonin secretion and circadian rhythm restoration in aging models (Khavinson 2003). Anisimov extended this to cancer and longevity studies, often noting that peptide bioregulators can modulate the sleep-wake cycle indirectly through neuroendocrine pathways. Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, and its primary mechanism involves modulation of GABAergic transmission and enkephalin degradation. Unlike benzodiazepines, Selank does not produce sedation or muscle relaxation in animal models; instead, it appears to reduce anxiety and improve cognitive function under stress. This anxiolytic profile is relevant for shift workers, because anxiety about sleep loss often perpetuates early awakenings.
In the Russian literature, Selank is frequently compared to DSIP (delta sleep-inducing peptide), another endogenous peptide studied for sleep regulation. A previous comparison on this site examined Selank versus DSIP for circadian rhythm repair after jet lag, noting that Selank's anxiolytic effect may be more useful when stress is the primary sleep disruptor. For shift workers, the stress component is often high, especially when combined with the metabolic changes induced by Retatrutide. Retatrutide's glucagon receptor agonism can increase energy expenditure and possibly alter sleep depth, though human data are scarce. Some users report early-morning awakenings during titration, but controlled studies are lacking. Selank's ability to reduce cortisol responses to stress (Sollertinskaya 2008) might counteract this, but the interaction between Selank and Retatrutide has not been formally studied.
Key Findings on Selank and Sleep Maintenance
Selank's effects on sleep have been studied in animal models and small human trials. In rats, Selank increased total sleep time and reduced wakefulness during the inactive phase, but did not alter sleep latency significantly (Sollertinskaya 2008). This suggests that Selank may be more useful for sleep maintenance than sleep onset. A separate study in humans with anxiety disorders found that Selank improved subjective sleep quality and reduced nighttime awakenings after two weeks of administration (Zozulya 2009). The mechanism is thought to involve modulation of the GABA-benzodiazepine receptor complex, but without the typical side effects of benzodiazepines. Selank also increases the expression of brain-derived neurotrophic factor (BDNF) in the hippocampus, which may support neuroplasticity during circadian shifts (Kolomin 2013).
For shift workers, the timing of Selank administration matters. Russian researchers often recommend using Selank during the daytime or early evening to reduce anxiety without causing sedation at night. However, no formal dosing guidelines exist for this context. In the context of Retatrutide, one must consider that GLP-1 receptor agonists can delay gastric emptying, which might affect the absorption of sublingually administered peptides like Selank. Selank is typically given intranasally or subcutaneously in research settings, bypassing the gastrointestinal tract. This is an advantage for shift workers who may have irregular meal times. But the combination of Retatrutide and Selank has not been tested in any published trial, so all discussion is speculative.
Another relevant peptide is Tesamorelin (a growth hormone-releasing hormone analogue), which has been studied for sleep architecture in GLP-1 users. A related article on Tesamorelin and Retatrutide stack for sleep architecture repair after GLP-1-induced REM suppression suggests that growth hormone pulses may help consolidate sleep. Selank and Tesamorelin act through different mechanisms, and some researchers hypothesize that combining them could address both anxiety and sleep depth. However, no clinical data support this combination, and the risk of polypharmacy in shift workers is real.
Circadian Re-Entrainment and the Role of Anxiolysis
Circadian re-entrainment after shift work requires not only sleep but also proper light exposure and meal timing. Selank does not directly shift the circadian clock like melatonin or light therapy. Instead, it may reduce the anxiety and hyperarousal that prevent the clock from stabilizing. In a study of shift workers with insomnia, Selank improved sleep efficiency and reduced the number of early-morning awakenings compared to placebo (Gromova 2015). The authors noted that the effect was most pronounced in workers with high baseline anxiety. This is consistent with Selank's known anxiolytic profile. However, the study did not include participants using Retatrutide or any GLP-1 agonist.
Retatrutide's triple agonism may cause weight loss and improvements in glucose control, but its effects on sleep are not well documented. Some GLP-1 agonists are associated with increased REM sleep latency and reduced REM duration, which can lead to non-restorative sleep. Tesamorelin has been proposed to counteract this, as discussed in Tesamorelin for jet lag. Selank, on the other hand, may improve sleep continuity by reducing nighttime cortisol spikes. Cortisol typically rises in the early morning hours, and in shift workers this rise can be exaggerated, leading to premature awakening. Selank's ability to blunt stress-induced cortisol release (Sollertinskaya 2008) could theoretically delay this awakening. But again, no direct evidence exists for the Selank plus Retatrutide combination.
One must also consider the role of DSIP (delta sleep-inducing peptide), which has been studied for sleep regulation in shift workers. A comparison of Selank versus DSIP for circadian resynchronization after shift work found that DSIP may be more directly hypnotic, while Selank is more anxiolytic. For a shift worker using Retatrutide, the choice between these peptides would depend on the primary sleep complaint: difficulty staying asleep (maintenance) versus difficulty falling asleep (onset). Selank appears better suited for maintenance insomnia, which is the focus of this article.
Open Questions and Limitations
The existing literature on Selank for sleep maintenance is small and mostly from Russian sources. Many studies are not randomized or blinded, and the sample sizes are often under 50 participants. The interaction between Selank and Retatrutide is completely unexplored. Retatrutide's long half-life and effects on gastric emptying could alter the pharmacokinetics of Selank if both are given subcutaneously. Additionally, shift workers are a heterogeneous group; night shift, rotating shift, and early morning shift have different circadian challenges. Selank may be more useful for rotating shift workers who experience anxiety about schedule changes, but this has not been tested.
Another open question is whether Selank's anxiolytic effect could mask the symptoms of an underlying sleep disorder, such as sleep apnea, which is common in shift workers and may be exacerbated by weight changes from Retatrutide. Tesamorelin and NAD+ have been studied for sleep-disordered breathing in GLP-1 users, as noted in a separate article on Tesamorelin and NAD+ for sleep-disordered breathing. Selank does not treat sleep apnea, and using it to reduce anxiety without addressing the apnea could be dangerous. Therefore, any research protocol involving Selank in shift workers using Retatrutide should include polysomnography to rule out sleep-disordered breathing.
Finally, the regulatory status of Selank varies by country. In Russia, it is approved as an anxiolytic medication. In the United States and Europe, it is not approved for human use and is sold only as a research chemical. Retatrutide is also investigational and not approved for any indication. Combining two investigational compounds in a shift worker population raises significant ethical and safety concerns. Long-term safety data for Selank is limited, and the peptide's effects on immune function (it is a tuftsin analogue) are not fully understood. Tuftsin stimulates phagocytosis, and chronic Selank use could theoretically alter immune responses. This is particularly relevant for shift workers, who already have altered immune function due to circadian disruption.
In summary, the hypothesis that Selank can prevent early-morning awakenings and support circadian re-entrainment in shift workers using Retatrutide is plausible but unproven. The Russian literature provides a foundation for Selank's anxiolytic and sleep-maintenance effects, but the combination with Retatrutide introduces too many unknowns. Researchers interested in this area should first conduct pharmacokinetic studies in animal models, then small human trials with careful sleep monitoring. Until such data exist, any claims about efficacy are speculative.
Regulatory status of peptides varies by country, state, and intended use; readers are responsible for verifying applicable rules.